Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Joao M Victor AlessiBiagio RicciutiElizabeth Jiménez-AguilarFangxin HongZihan WeiMizuki NishinoAndrew J PlodkowskiPeter SawanJia LuoHira RizviBrett W CarterJohn V HeymachMehmet AltanMatthew HellmannMark AwadPublished in: Journal for immunotherapy of cancer (2021)
A subset of patients with NSCLC and an ECOG PS of 2 can respond to first-line pembrolizumab. However, clinical outcomes in this population are often poor and use of second-line systemic therapy is infrequent.